Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GERN
Strong SellSinkerGeron Corporation · Healthcare · United States · $970M · Avg Vol: $16M/d
17
StockRankGet insider-trade alerts
Q
32
V
28
M
39
P/E (TTM)
—
ROE
-28.3%
D/E
0.6x
Dividend %
—
COMPANY DESCRIPTION
Geron Corporation is a biopharmaceutical company focused on the development of novel therapeutics for hematologic malignancies. Its lead product candidate, imetelstat, targets telomerase, a unique mechanism of action for specific blood cancers. Geron operates in a high-risk, high-reward niche, aiming to address significant unmet medical needs in oncology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.6M | 0.2M | 77.0M | 183.9M | 575.7% | 204.6M | 236.3M | 342.0M | 36.4% |
| EPS | -0.37 | -0.32 | -0.27 | -0.13 | — | -0.11 | — | — | — |
| Shares | 390.3M | 544.9M | 606.4M | 639.9M | +64.0% | 642.5M | — | — | — |
| Debt | 55.8M | 85.9M | 121.7M | 122.0M | 29.8% | 122.1M | — | — | — |
| Equity | 80.0M | 247.9M | 280.3M | 225.9M | 41.3% | — | — | — | — |
| Op CF | -127.4M | -167.7M | -218.6M | -111.0M | — | -114.4M | — | — | — |
| Inv CF | 62.1M | -180.3M | -106.0M | 107.2M | — | — | — | — | — |
| Fin CF | 87.3M | 362.0M | 334.4M | 2.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+0.0%
SMA 50SMA 200
Close
$1.40
RSI (14)
33.9
52W High
$2.01
From 52W High
0.7%
SCORE BREAKDOWN
Quality
32
ROIC
-8.1%36.4
ROE
-28.3%26.2
GP/Assets
21.0%46.8
Op. Margin
-22.0%24.5
FCF/Assets
-19.5%21.4
Piotroski
25.9
Int. Cover
-1.2x33.3
D/E Ratio
0.56x26.9
Current Ratio
6.92x80.5
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-23.9x25.0
P/FCF
—N/A
P/B
4.6x31.4
P/S
4.9x41.9
Div Yield
—N/A
Momentum
39
52W High %
70%49.6
RS 6M
-27%31.4
SMA 50/200
1.02x61.3
EPS Rev 4W
-33.3%2.2
EPS Rev 12W
-38.5%2.9
EPS Improve
+136%81.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$970M
P/E (Forward)
39.3x
Gross Margin
58.5%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GERN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GERN | Geron Corporation(you) | $970M | 17 | Strong Sell |
| ARDX | Ardelyx, Inc. | $984M | 14 | Strong Sell |
| SGP | SpyGlass Pharma, Inc. | $884M | 14 | Strong Sell |
| ACHV | Achieve Life Sciences, Inc. | $834M | 19 | Strong Sell |
| STTK | Shattuck Labs, Inc. | $707M | 17 | Strong Sell |
| SVRA | Savara Inc. | $1.1B | 12 | Strong Sell |
| PHAT | Phathom Pharmaceuticals, Inc. | $743M | 14 | Strong Sell |
| ACRS | Aclaris Therapeutics, Inc. | $885M | 24 | Sell |
| ABSI | Absci Corporation | $1.5B | 17 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.1B | 11 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%